<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02262728</url>
  </required_header>
  <id_info>
    <org_study_id>CR105028</org_study_id>
    <secondary_id>TMC435HPC2010</secondary_id>
    <nct_id>NCT02262728</nct_id>
  </id_info>
  <brief_title>An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease</brief_title>
  <official_title>A Phase 2 Open-label Study to Investigate the Efficacy, Safety and Pharmacokinetics of 12 Weeks of Treatment With Simeprevir, Daclatasvir and Sofosbuvir, Followed by a 5-Year Post-treatment Long-term Follow-up, in Treatment-na√Øve and Treatment-experienced Subjects With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of a 12-week regimen containing
      simeprevir, daclatasvir and sofosbuvir in participants with decompensated liver disease (the
      liver function is insufficient) due to genotype 1 or 4 Hepatitis (inflammation of the liver)
      C virus (HCV) infection by assessing sustained virologic response 12-weeks after the end of
      study drug treatment (SVR12).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label (all people know which treatment the participants receive) Phase 2
      study to investigate the efficacy, safety and pharmacokinetics of simeprevir, daclatasvir and
      sofosbuvir in treatment-naive (participants have never received HCV treatment with any
      approved or investigational agent) and treatment - experienced (participants have failed at
      least one previous course of [Pegylated] interferon [(Peg)IFN], with or without Ribavirin)
      participants. Participants will be assigned to 1 of 2 panels: Panel 1 (n=20): Child-Pugh
      score less than (&lt;) 7 with evidence of portal hypertension (confirmed by presence of
      esophageal varices or HVPG greater than or equal to [&gt;=] 10 mm Hg); Panel 2 (n=20):
      Child-Pugh score 7 to 9 (extremes included). The total study duration for each participant
      will be approximately 276 weeks. The study will consist of 3 parts: Screening Phase
      (approximately 4 weeks) and open-label treatment Phase (from Week 4 to 16) and follow-up
      Phase (until 5 years after the actual end of study drug treatment). Participants will receive
      simeprevir (150 milligram [mg] capsule), daclatasvir (60 mg tablet) and sofosbuvir (400 mg
      tablet) orally once daily for 12 weeks. Efficacy will be primarily evaluated by percentage of
      participants with SVR12. Participants' safety will be monitored throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 30, 2014</start_date>
  <completion_date type="Anticipated">December 5, 2019</completion_date>
  <primary_completion_date type="Actual">August 13, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After End of Study Drug Treatment (SVR12)</measure>
    <time_frame>Week 24</time_frame>
    <description>Participants were considered to have achieved SVR12 if the hepatitis C virus ribonucleic acid (HCV RNA) was less than (&lt;) lower limit of quantification (LLOQ; 15 international unit per milliliter [IU/mL]) detectable or undetectable at 12 weeks after the end of study drug treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With On-Treatment Virologic Response</measure>
    <time_frame>Week 1, 2, 4, 6, 8, 10, 12</time_frame>
    <description>On-treatment virologic response was determined by HCV RNA results satisfying a specified threshold. The following thresholds were considered at any time point: &lt;LLOQ undetectable, &lt;LLOQ detectable, and &lt;LLOQ undetectable or detectable. The LLOQ value was 15 IU/mL. Very rapid virologic response (vRVR) is undetectable HCV RNA at Week 2 while on treatment and Rapid virologic response (RVR) is undetectable HCV RNA at Week 4 while on treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With SVR 4 Weeks After End of Study Drug Treatment (SVR4) and SVR 24 Weeks After End of Study Drug Treatment (SVR24)</measure>
    <time_frame>Week 16 and Week 36</time_frame>
    <description>Participants were considered to have achieved SVR4 and SVR24 if the HCV RNA was &lt;LLOQ detectable or undetectable at 4 weeks and 24 weeks respectively after the end of study drug treatment. The LLOQ value was 15 IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HCV NS3/4A Sequence, NS5A and NS5B After End of Treatment in Participants Not Achieving SVR</measure>
    <time_frame>Baseline, Day 3, Week 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, and Year 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5 after end of treatment</time_frame>
    <description>Sequencing of the HCV nonstructural protein 3/4A (NS3/4A), nonstructural protein 5A (NS5A) and nonstructural protein 5B (NS5B) genes was done to identify pre-existing sequence polymorphisms and characterize emerging HCV viral variants in participants not achieving SVR. All subjects in this study achieved SVR12. Therefore, reasons for not achieving SVR12 are not applicable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) Levels at Follow-up Week 24 (Week 36)</measure>
    <time_frame>Follow-up Week 24 (Week 36)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration (Tmax) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir Metabolite)</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours post-dose on Weeks 2 and 8</time_frame>
    <description>Tmax is the time to reach maximum observed plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours After Dosing (AUC[0-24]) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir Metabolite)</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours post-dose on Weeks 2 and 8</time_frame>
    <description>The AUC(0-24) is area under the plasma concentration-time curve from time 0 to 24 hours after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir Metabolite)</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours post-dose on Weeks 2 and 8</time_frame>
    <description>The Cmax is the maximum observed plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Plasma Concentration (Cmin) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir Metabolite)</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours post-dose on Weeks 2 and 8</time_frame>
    <description>The Cmin is the minimum observed plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose (Trough) Concentration (C0h) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir Metabolite)</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours post-dose on Weeks 2 and 8</time_frame>
    <description>The C0h is the pre-dose plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With On-treatment Failure</measure>
    <time_frame>Week 12</time_frame>
    <description>On-treatment failure is defined as participants who do not achieve SVR12 and with confirmed detectable HCV RNA at the actual end of study drug treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Viral Relapse</measure>
    <time_frame>Week 16, 24 and 36</time_frame>
    <description>Viral relapse is defined as participants who do not achieve SVR12, with undetectable HCV RNA at the actual end of study drug treatment and confirmed HCV RNA greater than or equal to (&gt;=) LLOQ (15 IU/mL) at Week 16, 24 or 36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With SVR12 Who Maintain to Have HCV RNA &lt;LLOQ Until the End of 5 Years Follow up</measure>
    <time_frame>Week 24 up to Week 276</time_frame>
    <description>Percentage of participants with SVR12 who continue to have HCV RNA &lt;LLOQ (15 IU/mL) will be reported after the completion of the follow-up phase.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Panel 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Child-Pugh score &lt;7 with evidence of portal hypertension (confirmed by presence of esophageal varices or hepatic venous pressure gradient [HVPG] greater than or equal to 10 millimeter of mercury [mm Hg]) will receive simeprevir (150 milligram [mg] capsule), daclatasvir (60 mg tablet) and sofosbuvir (400 mg tablet) orally once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Child-Pugh score 7 to 9 (extremes included) will receive simeprevir (150 mg capsule), daclatasvir (60 mg tablet) and sofosbuvir (400 mg tablet) orally once daily for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simeprevir</intervention_name>
    <description>Simeprevir 150 milligram (mg) capsule orally once daily for 12 weeks</description>
    <arm_group_label>Panel 1</arm_group_label>
    <arm_group_label>Panel 2</arm_group_label>
    <other_name>TMC435</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclatasvir</intervention_name>
    <description>Daclatasvir 60 mg tablet orally once daily for 12 weeks</description>
    <arm_group_label>Panel 1</arm_group_label>
    <arm_group_label>Panel 2</arm_group_label>
    <other_name>BMS-790052</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir</intervention_name>
    <description>Sofosbuvir 400 mg tablet orally once daily for 12 weeks</description>
    <arm_group_label>Panel 1</arm_group_label>
    <arm_group_label>Panel 2</arm_group_label>
    <other_name>GS-7977</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented chronic Hepatitis C virus (HCV) infection: diagnosis of HCV more than (&gt;) 6
             months before the Screening visit, either by detectable HCV ribonucleic acid (RNA), a
             HCV positive antibody or the presence of histological changes consistent with chronic
             hepatitis

          -  HCV genotype 1 or 4 infection and HCV RNA plasma level &gt;10,000 international unit per
             milliliter (IU/mL) (both determined at screening)

          -  Presence of cirrhosis, which is defined as a FibroScan with a result of &gt;14.5
             kilopascals (kPa) at Screening

          -  HCV treatment-naive participants: participant has not received treatment with any
             approved or investigational drug for the treatment of HCV infection and HCV
             treatment-experienced participants: participant has had at least 1 documented previous
             course of a non-direct-acting antiviral agent (DAA), interferon (IFN)-based HCV
             therapy (with or without Ribavirin [RBV]). Last dose in this previous course should
             have occurred at least 2 months prior to Screening

          -  Decompensated liver disease: Panel 1: Child Pugh A (mild hepatic impairment) with
             evidence of portal hypertension [confirmed by the presence of esophageal varices on
             gastroscopy or hepatic venous pressure gradient (HVPG) greater than or equal to (&gt;=)
             10 millimeter of mercury (mm Hg)], Panel 2: Child-Pugh B (moderate hepatic impairment)
             7 to 9 (extremes included)

        Exclusion Criteria:

          -  Co-infection with any HCV genotype

          -  Co-infection with human immunodeficiency virus (HIV)-1 or -2 (positive HIV-1 or HIV-2
             antibodies test at Screening)

          -  Co-infection with hepatitis B virus (hepatitis B surface antigen [HBsAg] positive)

          -  Any evidence of liver disease of non-HCV etiology. This includes, but is not limited
             to, acute hepatitis A infection, drug- or alcohol-related liver disease, autoimmune
             hepatitis, hemochromatosis, Wilson's disease, alpha-1 antitrypsin deficiency,
             non-alcoholic steatohepatitis, primary biliary cirrhosis, or any other non-HCV liver
             disease considered clinically significant by the Investigator

          -  Use of any disallowed therapies before the planned first dose of study drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2014</study_first_submitted>
  <study_first_submitted_qc>October 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2014</study_first_posted>
  <results_first_submitted>August 16, 2016</results_first_submitted>
  <results_first_submitted_qc>December 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 13, 2017</results_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C, Chronic</keyword>
  <keyword>Simeprevir</keyword>
  <keyword>Daclatasvir</keyword>
  <keyword>Sofosbuvir</keyword>
  <keyword>Decompensated Liver Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Simeprevir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SMV 150mg/DCV 60mg/SOF 400mg - Child-Pugh A</title>
          <description>Participants with Child-Pugh score &lt;7 with evidence of portal hypertension (confirmed by presence of esophageal varices or hepatic venous pressure gradient [HVPG] greater than or equal to 10 millimeter of mercury [mm Hg]) received simeprevir (SMV) (150 milligram [mg] capsule), daclatasvir (DCV) (60 mg tablet) and sofosbuvir (SOF) (400 mg tablet) orally once daily for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>SMV 150mg/DCV 60mg/SOF 400mg - Child-Pugh B</title>
          <description>Participants with Child-Pugh score 7 to 9 (extremes included) received simeprevir (SMV) (150 mg capsule), daclatasvir (DCV) (60 mg tablet) and sofosbuvir (SOF) (400 mg tablet) orally once daily for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SMV 150mg/DCV 60mg/SOF 400mg - Child-Pugh A</title>
          <description>Participants with Child-Pugh score &lt;7 with evidence of portal hypertension (confirmed by presence of esophageal varices or hepatic venous pressure gradient [HVPG] greater than or equal to 10 millimeter of mercury [mm Hg]) received simeprevir (SMV) (150 milligram [mg] capsule), daclatasvir (DCV) (60 mg tablet) and sofosbuvir (SOF) (400 mg tablet) orally once daily for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>SMV 150mg/DCV 60mg/SOF 400mg - Child-Pugh B</title>
          <description>Participants with Child-Pugh score 7 to 9 (extremes included) received simeprevir (SMV) (150 mg capsule), daclatasvir (DCV) (60 mg tablet) and sofosbuvir (SOF) (400 mg tablet) orally once daily for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" lower_limit="30" upper_limit="64"/>
                    <measurement group_id="B2" value="61" lower_limit="50" upper_limit="75"/>
                    <measurement group_id="B3" value="58.5" lower_limit="30" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Sustained Virologic Response 12 Weeks After End of Study Drug Treatment (SVR12)</title>
        <description>Participants were considered to have achieved SVR12 if the hepatitis C virus ribonucleic acid (HCV RNA) was less than (&lt;) lower limit of quantification (LLOQ; 15 international unit per milliliter [IU/mL]) detectable or undetectable at 12 weeks after the end of study drug treatment.</description>
        <time_frame>Week 24</time_frame>
        <population>The intent-to-treat (ITT) analysis set included all enrolled participants who took at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>SMV 150mg/DCV 60mg/SOF 400mg - Child-Pugh A</title>
            <description>Participants with Child-Pugh score &lt;7 with evidence of portal hypertension (confirmed by presence of esophageal varices or hepatic venous pressure gradient [HVPG] greater than or equal to 10 millimeter of mercury [mm Hg]) received simeprevir (SMV) (150 milligram [mg] capsule), daclatasvir (DCV) (60 mg tablet) and sofosbuvir (SOF) (400 mg tablet) orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>SMV 150mg/DCV 60mg/SOF 400mg - Child-Pugh B</title>
            <description>Participants with Child-Pugh score 7 to 9 (extremes included) received simeprevir (SMV) (150 mg capsule), daclatasvir (DCV) (60 mg tablet) and sofosbuvir (SOF) (400 mg tablet) orally once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sustained Virologic Response 12 Weeks After End of Study Drug Treatment (SVR12)</title>
          <description>Participants were considered to have achieved SVR12 if the hepatitis C virus ribonucleic acid (HCV RNA) was less than (&lt;) lower limit of quantification (LLOQ; 15 international unit per milliliter [IU/mL]) detectable or undetectable at 12 weeks after the end of study drug treatment.</description>
          <population>The intent-to-treat (ITT) analysis set included all enrolled participants who took at least 1 dose of study drug.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="82.4" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="83.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With On-Treatment Virologic Response</title>
        <description>On-treatment virologic response was determined by HCV RNA results satisfying a specified threshold. The following thresholds were considered at any time point: &lt;LLOQ undetectable, &lt;LLOQ detectable, and &lt;LLOQ undetectable or detectable. The LLOQ value was 15 IU/mL. Very rapid virologic response (vRVR) is undetectable HCV RNA at Week 2 while on treatment and Rapid virologic response (RVR) is undetectable HCV RNA at Week 4 while on treatment.</description>
        <time_frame>Week 1, 2, 4, 6, 8, 10, 12</time_frame>
        <population>The intent-to-treat (ITT) analysis set included all enrolled participants who took at least 1 dose of study drug. Here, 'n' signifies number of participants evaluable for this outcome measure at specific time point.</population>
        <group_list>
          <group group_id="O1">
            <title>SMV 150mg/DCV 60mg/SOF 400mg - Child-Pugh A</title>
            <description>Participants with Child-Pugh score &lt;7 with evidence of portal hypertension (confirmed by presence of esophageal varices or hepatic venous pressure gradient [HVPG] greater than or equal to 10 millimeter of mercury [mm Hg]) received simeprevir (SMV) (150 milligram [mg] capsule), daclatasvir (DCV) (60 mg tablet) and sofosbuvir (SOF) (400 mg tablet) orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>SMV 150mg/DCV 60mg/SOF 400mg - Child-Pugh B</title>
            <description>Participants with Child-Pugh score 7 to 9 (extremes included) received simeprevir (SMV) (150 mg capsule), daclatasvir (DCV) (60 mg tablet) and sofosbuvir (SOF) (400 mg tablet) orally once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With On-Treatment Virologic Response</title>
          <description>On-treatment virologic response was determined by HCV RNA results satisfying a specified threshold. The following thresholds were considered at any time point: &lt;LLOQ undetectable, &lt;LLOQ detectable, and &lt;LLOQ undetectable or detectable. The LLOQ value was 15 IU/mL. Very rapid virologic response (vRVR) is undetectable HCV RNA at Week 2 while on treatment and Rapid virologic response (RVR) is undetectable HCV RNA at Week 4 while on treatment.</description>
          <population>The intent-to-treat (ITT) analysis set included all enrolled participants who took at least 1 dose of study drug. Here, 'n' signifies number of participants evaluable for this outcome measure at specific time point.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 : &gt;= 15 IU/mL (n= 18, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2"/>
                    <measurement group_id="O2" value="76.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 : &lt; 100 IU/mL (n= 18, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.1"/>
                    <measurement group_id="O2" value="38.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1: &lt; 15 IU/mL undetect/detectable (n=18, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8"/>
                    <measurement group_id="O2" value="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 : &lt; 15 IU/mL detectable (n= 18, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 : &lt; 15 IU/mL Undetectable (n= 18, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 : &gt;= 15 IU/mL (n= 19, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5"/>
                    <measurement group_id="O2" value="47.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 : &lt; 100 IU/mL (n= 19, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.7"/>
                    <measurement group_id="O2" value="71.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: &lt; 15 IU/mL undetect/detectable (n=19, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.5"/>
                    <measurement group_id="O2" value="52.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 : &lt; 15 IU/mL detectable (n= 19, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.8"/>
                    <measurement group_id="O2" value="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: &lt; 15 IU/mL undetectable (vRVR) (n= 19, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.6"/>
                    <measurement group_id="O2" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 : &gt;= 15 IU/mL (n= 18, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 : &lt; 100 IU/mL (n= 18, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: &lt; 15 IU/mL undetect/detectable (n=18, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="90.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 : &lt; 15 IU/mL detectable (n= 18, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 : &lt; 15 IU/mL undetectable (RVR) (n= 18, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.4"/>
                    <measurement group_id="O2" value="61.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 : &gt;= 15 IU/mL (n= 19, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 : &lt; 100 IU/mL (n= 19, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6: &lt; 15 IU/mL undetect/detectable (n=19, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 : &lt; 15 IU/mL detectable (n= 19, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 : &lt; 15 IU/mL undetectable (n= 19, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.7"/>
                    <measurement group_id="O2" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 : &gt;= 15 IU/mL (n= 18, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 : &lt; 100 IU/mL (n= 18, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: &lt; 15 IU/mL undetect/detectable (n=18, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 : &lt; 15 IU/mL detectable (n= 18, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 : &lt; 15 IU/mL undetectable (n= 18, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="95.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 : &gt;= 15 IU/mL (n= 18, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 : &lt; 100 IU/mL (n= 18, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10: &lt; 15 IU/mL undetect/detectable (n=18,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 : &lt; 15 IU/mL detectable (n= 18, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 : &lt; 15 IU/mL undetectable (n= 18, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 : &gt;= 15 IU/mL (n= 17, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 :&lt; 100 IU/mL (n= 17, 19 )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: &lt; 15 IU/mL undetect/detectable (n=17, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 : &lt; 15 IU/mL detectable (n= 17, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 : &lt; 15 IU/mL undetectable (n= 17, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With SVR 4 Weeks After End of Study Drug Treatment (SVR4) and SVR 24 Weeks After End of Study Drug Treatment (SVR24)</title>
        <description>Participants were considered to have achieved SVR4 and SVR24 if the HCV RNA was &lt;LLOQ detectable or undetectable at 4 weeks and 24 weeks respectively after the end of study drug treatment. The LLOQ value was 15 IU/mL.</description>
        <time_frame>Week 16 and Week 36</time_frame>
        <population>The intent-to-treat (ITT) analysis set included all enrolled participants who took at least 1 dose of study drug. Here , 'n' signifies number of participants evaluable for this outcome measure at specific time point.</population>
        <group_list>
          <group group_id="O1">
            <title>SMV 150mg/DCV 60mg/SOF 400mg - Child-Pugh A</title>
            <description>Participants with Child-Pugh score &lt;7 with evidence of portal hypertension (confirmed by presence of esophageal varices or hepatic venous pressure gradient [HVPG] greater than or equal to 10 millimeter of mercury [mm Hg]) received simeprevir (SMV) (150 milligram [mg] capsule), daclatasvir (DCV) (60 mg tablet) and sofosbuvir (SOF) (400 mg tablet) orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>SMV 150mg/DCV 60mg/SOF 400mg - Child-Pugh B</title>
            <description>Participants with Child-Pugh score 7 to 9 (extremes included) received simeprevir (SMV) (150 mg capsule), daclatasvir (DCV) (60 mg tablet) and sofosbuvir (SOF) (400 mg tablet) orally once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With SVR 4 Weeks After End of Study Drug Treatment (SVR4) and SVR 24 Weeks After End of Study Drug Treatment (SVR24)</title>
          <description>Participants were considered to have achieved SVR4 and SVR24 if the HCV RNA was &lt;LLOQ detectable or undetectable at 4 weeks and 24 weeks respectively after the end of study drug treatment. The LLOQ value was 15 IU/mL.</description>
          <population>The intent-to-treat (ITT) analysis set included all enrolled participants who took at least 1 dose of study drug. Here , 'n' signifies number of participants evaluable for this outcome measure at specific time point.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR 4 n = (19, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="82.4" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="83.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR 24 n = (19, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="82.4" upper_limit="100"/>
                    <measurement group_id="O2" value="100">95% Confidence Interval was not calculated since less than 10 participants were evaluable for the specific arm group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HCV NS3/4A Sequence, NS5A and NS5B After End of Treatment in Participants Not Achieving SVR</title>
        <description>Sequencing of the HCV nonstructural protein 3/4A (NS3/4A), nonstructural protein 5A (NS5A) and nonstructural protein 5B (NS5B) genes was done to identify pre-existing sequence polymorphisms and characterize emerging HCV viral variants in participants not achieving SVR. All subjects in this study achieved SVR12. Therefore, reasons for not achieving SVR12 are not applicable.</description>
        <time_frame>Baseline, Day 3, Week 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, and Year 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5 after end of treatment</time_frame>
        <population>The ITT analysis set who failed achieving SVR. Since all participants achieved SVR, the number of participants for this endpoint analysis was zero.</population>
        <group_list>
          <group group_id="O1">
            <title>SMV 150mg/DCV 60mg/SOF 400mg - Child-Pugh A</title>
            <description>Participants with Child-Pugh score &lt;7 with evidence of portal hypertension (confirmed by presence of esophageal varices or hepatic venous pressure gradient [HVPG] greater than or equal to 10 millimeter of mercury [mm Hg]) received simeprevir (SMV) (150 milligram [mg] capsule), daclatasvir (DCV) (60 mg tablet) and sofosbuvir (SOF) (400 mg tablet) orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>SMV 150mg/DCV 60mg/SOF 400mg - Child-Pugh B</title>
            <description>Participants with Child-Pugh score 7 to 9 (extremes included) received simeprevir (SMV) (150 mg capsule), daclatasvir (DCV) (60 mg tablet) and sofosbuvir (SOF) (400 mg tablet) orally once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HCV NS3/4A Sequence, NS5A and NS5B After End of Treatment in Participants Not Achieving SVR</title>
          <description>Sequencing of the HCV nonstructural protein 3/4A (NS3/4A), nonstructural protein 5A (NS5A) and nonstructural protein 5B (NS5B) genes was done to identify pre-existing sequence polymorphisms and characterize emerging HCV viral variants in participants not achieving SVR. All subjects in this study achieved SVR12. Therefore, reasons for not achieving SVR12 are not applicable.</description>
          <population>The ITT analysis set who failed achieving SVR. Since all participants achieved SVR, the number of participants for this endpoint analysis was zero.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) Levels at Follow-up Week 24 (Week 36)</title>
        <time_frame>Follow-up Week 24 (Week 36)</time_frame>
        <population>The intent-to-treat (ITT) analysis set included all enrolled participants who took at least 1 dose of study drug. Here, 'n' signifies number of participants evaluable for this outcome measure at specific time point.</population>
        <group_list>
          <group group_id="O1">
            <title>SMV 150mg/DCV 60mg/SOF 400mg - Child-Pugh A</title>
            <description>Participants with Child-Pugh score &lt;7 with evidence of portal hypertension (confirmed by presence of esophageal varices or hepatic venous pressure gradient [HVPG] greater than or equal to 10 millimeter of mercury [mm Hg]) received simeprevir (SMV) (150 milligram [mg] capsule), daclatasvir (DCV) (60 mg tablet) and sofosbuvir (SOF) (400 mg tablet) orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>SMV 150mg/DCV 60mg/SOF 400mg - Child-Pugh B</title>
            <description>Participants with Child-Pugh score 7 to 9 (extremes included) received simeprevir (SMV) (150 mg capsule), daclatasvir (DCV) (60 mg tablet) and sofosbuvir (SOF) (400 mg tablet) orally once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) Levels at Follow-up Week 24 (Week 36)</title>
          <population>The intent-to-treat (ITT) analysis set included all enrolled participants who took at least 1 dose of study drug. Here, 'n' signifies number of participants evaluable for this outcome measure at specific time point.</population>
          <units>Units per Liter (U/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline : ALT (n = 19, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.8" spread="101.90"/>
                    <measurement group_id="O2" value="60.9" spread="29.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline : AST (n = 19, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.1" spread="80.57"/>
                    <measurement group_id="O2" value="83.5" spread="35.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-Up Week 24 : ALT (n = 18, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.8" spread="11.30"/>
                    <measurement group_id="O2" value="32.3" spread="9.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-Up Week 24 : AST (n = 18, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.2" spread="21.86"/>
                    <measurement group_id="O2" value="35.0" spread="10.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Plasma Concentration (Tmax) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir Metabolite)</title>
        <description>Tmax is the time to reach maximum observed plasma concentration.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours post-dose on Weeks 2 and 8</time_frame>
        <population>Pharmacokinetic (PK) analysis set included all participants who received atleast 1 dose of study drug and had valid pharmacokinetic profile. Here 'n' signifies number of participants analysed for this outcome measure at specific time point.</population>
        <group_list>
          <group group_id="O1">
            <title>SMV 150mg/DCV 60mg/SOF 400mg - Child-Pugh A</title>
            <description>Participants with Child-Pugh score &lt;7 with evidence of portal hypertension (confirmed by presence of esophageal varices or hepatic venous pressure gradient [HVPG] greater than or equal to 10 millimeter of mercury [mm Hg]) received simeprevir (SMV) (150 milligram [mg] capsule), daclatasvir (DCV) (60 mg tablet) and sofosbuvir (SOF) (400 mg tablet) orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>SMV 150mg/DCV 60mg/SOF 400mg - Child-Pugh B</title>
            <description>Participants with Child-Pugh score 7 to 9 (extremes included) received simeprevir (SMV) (150 mg capsule), daclatasvir (DCV) (60 mg tablet) and sofosbuvir (SOF) (400 mg tablet) orally once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Plasma Concentration (Tmax) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir Metabolite)</title>
          <description>Tmax is the time to reach maximum observed plasma concentration.</description>
          <population>Pharmacokinetic (PK) analysis set included all participants who received atleast 1 dose of study drug and had valid pharmacokinetic profile. Here 'n' signifies number of participants analysed for this outcome measure at specific time point.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Simeprevir: Week 2 (n = 19, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.00" lower_limit="4.00" upper_limit="12.00"/>
                    <measurement group_id="O2" value="8.00" lower_limit="2.00" upper_limit="24.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Simeprevir: Week 8 (n = 18, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.00" lower_limit="3.00" upper_limit="12.00"/>
                    <measurement group_id="O2" value="8.00" lower_limit="0.50" upper_limit="24.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daclatasvir: Week 2 (n = 18, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="0.50" upper_limit="6.00"/>
                    <measurement group_id="O2" value="4.00" lower_limit="1.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daclatasvir: Week 8 (n = 18, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" lower_limit="0.00" upper_limit="8.00"/>
                    <measurement group_id="O2" value="4.00" lower_limit="0.00" upper_limit="12.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sofosbuvir: Week 2 (n = 18, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.50" upper_limit="4.00"/>
                    <measurement group_id="O2" value="2.00" lower_limit="0.50" upper_limit="4.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sofosbuvir: Week 8 (n = 18, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" lower_limit="0.50" upper_limit="12.00"/>
                    <measurement group_id="O2" value="2.00" lower_limit="1.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GS-331007: Week 2 (n = 18, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" lower_limit="1.50" upper_limit="4.17"/>
                    <measurement group_id="O2" value="4.00" lower_limit="1.50" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GS-331007: Week 8 (n = 18, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" lower_limit="2.00" upper_limit="12.00"/>
                    <measurement group_id="O2" value="4.00" lower_limit="3.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours After Dosing (AUC[0-24]) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir Metabolite)</title>
        <description>The AUC(0-24) is area under the plasma concentration-time curve from time 0 to 24 hours after dosing.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours post-dose on Weeks 2 and 8</time_frame>
        <population>Pharmacokinetic (PK) analysis set included all participants who received atleast 1 dose of study drug and had valid pharmacokinetic profile. Here 'n' signifies number of participants analysed for this outcome measure at specific time point.</population>
        <group_list>
          <group group_id="O1">
            <title>SMV 150mg/DCV 60mg/SOF 400mg - Child-Pugh A</title>
            <description>Participants with Child-Pugh score &lt;7 with evidence of portal hypertension (confirmed by presence of esophageal varices or hepatic venous pressure gradient [HVPG] greater than or equal to 10 millimeter of mercury [mm Hg]) received simeprevir (SMV) (150 milligram [mg] capsule), daclatasvir (DCV) (60 mg tablet) and sofosbuvir (SOF) (400 mg tablet) orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>SMV 150mg/DCV 60mg/SOF 400mg - Child-Pugh B</title>
            <description>Participants with Child-Pugh score 7 to 9 (extremes included) received simeprevir (SMV) (150 mg capsule), daclatasvir (DCV) (60 mg tablet) and sofosbuvir (SOF) (400 mg tablet) orally once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours After Dosing (AUC[0-24]) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir Metabolite)</title>
          <description>The AUC(0-24) is area under the plasma concentration-time curve from time 0 to 24 hours after dosing.</description>
          <population>Pharmacokinetic (PK) analysis set included all participants who received atleast 1 dose of study drug and had valid pharmacokinetic profile. Here 'n' signifies number of participants analysed for this outcome measure at specific time point.</population>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Simeprevir : Week 2 (n = 19, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113835" spread="91598"/>
                    <measurement group_id="O2" value="142162" spread="80217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Simeprevir : Week 8 (n = 18, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98568" spread="80037"/>
                    <measurement group_id="O2" value="207221" spread="162168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daclatasvir : Week 2 (n = 18, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16487" spread="6323"/>
                    <measurement group_id="O2" value="17858" spread="7726"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daclatasvir : Week 8 (n = 18, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15574" spread="5347"/>
                    <measurement group_id="O2" value="20787" spread="10741"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sofosbuvir : Week 2 (n = 18, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2870" spread="978"/>
                    <measurement group_id="O2" value="3915" spread="1258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sofosbuvir : Week 8 (n = 18, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2746" spread="963"/>
                    <measurement group_id="O2" value="3933" spread="1315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GS-331007 : Week 2 (n = 18, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17900" spread="6320"/>
                    <measurement group_id="O2" value="21118" spread="11301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GS-331007 : Week 8 (n = 18, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18132" spread="7469"/>
                    <measurement group_id="O2" value="22829" spread="15394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (Cmax) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir Metabolite)</title>
        <description>The Cmax is the maximum observed plasma concentration.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours post-dose on Weeks 2 and 8</time_frame>
        <population>Pharmacokinetic (PK) analysis set included all participants who received atleast 1 dose of study drug and had valid pharmacokinetic profile. Here 'n' signifies number of participants analysed for this outcome measure at specific time point.</population>
        <group_list>
          <group group_id="O1">
            <title>SMV 150mg/DCV 60mg/SOF 400mg - Child-Pugh A</title>
            <description>Participants with Child-Pugh score &lt;7 with evidence of portal hypertension (confirmed by presence of esophageal varices or hepatic venous pressure gradient [HVPG] greater than or equal to 10 millimeter of mercury [mm Hg]) received simeprevir (SMV) (150 milligram [mg] capsule), daclatasvir (DCV) (60 mg tablet) and sofosbuvir (SOF) (400 mg tablet) orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>SMV 150mg/DCV 60mg/SOF 400mg - Child-Pugh B</title>
            <description>Participants with Child-Pugh score 7 to 9 (extremes included) received simeprevir (SMV) (150 mg capsule), daclatasvir (DCV) (60 mg tablet) and sofosbuvir (SOF) (400 mg tablet) orally once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir Metabolite)</title>
          <description>The Cmax is the maximum observed plasma concentration.</description>
          <population>Pharmacokinetic (PK) analysis set included all participants who received atleast 1 dose of study drug and had valid pharmacokinetic profile. Here 'n' signifies number of participants analysed for this outcome measure at specific time point.</population>
          <units>nanogram per Millilieters (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Simeprevir : Week 2 (reference) n = 19, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6976" spread="4439"/>
                    <measurement group_id="O2" value="7726" spread="3946"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Simeprevir : Week 8 (test) n = 18, 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6029" spread="3936"/>
                    <measurement group_id="O2" value="10498" spread="7492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daclatasvir : Week 2 n = 18, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1187" spread="397"/>
                    <measurement group_id="O2" value="1145" spread="440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daclatasvir : Week 8 n = 18, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1072" spread="313"/>
                    <measurement group_id="O2" value="1210" spread="543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sofosbuvir : Week 2 n = 18, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1571" spread="738"/>
                    <measurement group_id="O2" value="1615" spread="986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sofosbuvir : Week 8 n = 18, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1276" spread="856"/>
                    <measurement group_id="O2" value="1527" spread="993"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GS-331007 : Week 2 n = 18, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1403" spread="369"/>
                    <measurement group_id="O2" value="1561" spread="720"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GS-331007 : Week 8 n = 18, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1404" spread="361"/>
                    <measurement group_id="O2" value="1594" spread="952"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimum Plasma Concentration (Cmin) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir Metabolite)</title>
        <description>The Cmin is the minimum observed plasma concentration.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours post-dose on Weeks 2 and 8</time_frame>
        <population>PK analysis set included all participants who received atleast 1 dose of study drug and had valid pharmacokinetic profile. Here 'n' signifies number of participants analysed for this outcome measure at specific time point.</population>
        <group_list>
          <group group_id="O1">
            <title>SMV 150mg/DCV 60mg/SOF 400mg - Child-Pugh A</title>
            <description>Participants with Child-Pugh score &lt;7 with evidence of portal hypertension (confirmed by presence of esophageal varices or hepatic venous pressure gradient [HVPG] greater than or equal to 10 millimeter of mercury [mm Hg]) received simeprevir (SMV) (150 milligram [mg] capsule), daclatasvir (DCV) (60 mg tablet) and sofosbuvir (SOF) (400 mg tablet) orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>SMV 150mg/DCV 60mg/SOF 400mg - Child-Pugh B</title>
            <description>Participants with Child-Pugh score 7 to 9 (extremes included) received simeprevir (SMV) (150 mg capsule), daclatasvir (DCV) (60 mg tablet) and sofosbuvir (SOF) (400 mg tablet) orally once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum Plasma Concentration (Cmin) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir Metabolite)</title>
          <description>The Cmin is the minimum observed plasma concentration.</description>
          <population>PK analysis set included all participants who received atleast 1 dose of study drug and had valid pharmacokinetic profile. Here 'n' signifies number of participants analysed for this outcome measure at specific time point.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Simeprevir : Week 2 (n = 19, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3133" spread="3410"/>
                    <measurement group_id="O2" value="4363" spread="3081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Simeprevir : Week 8 (n = 18, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2639" spread="2725"/>
                    <measurement group_id="O2" value="6955" spread="6035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daclatasvir : Week 2 (n = 19, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="414" spread="230"/>
                    <measurement group_id="O2" value="519" spread="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daclatasvir : Week 8 (n = 18, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="442" spread="192"/>
                    <measurement group_id="O2" value="660" spread="416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sofosbuvir : Week 2 (n = 19, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not reported as participants had concentration below the limit of quantification (less than [&lt;]5.00 nanogram/millilter [ng/mL])</measurement>
                    <measurement group_id="O2" value="NA">Data was not reported as participants had concentration below the limit of quantification (less than [&lt;]5.00 nanogram/millilter [ng/mL])</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sofosbuvir : Week 8 (n = 18, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not reported as participants had concentration below the limit of quantification (less than [&lt;]5.00 nanogram/millilter [ng/mL])</measurement>
                    <measurement group_id="O2" value="NA">Data was not reported as participants had concentration below the limit of quantification (less than [&lt;]5.00 nanogram/millilter [ng/mL])</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GS-331007 : Week 2 (n = 19, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="419" spread="198"/>
                    <measurement group_id="O2" value="441" spread="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GS-331007 : Week 8 (n = 18, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="443" spread="213"/>
                    <measurement group_id="O2" value="523" spread="392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-dose (Trough) Concentration (C0h) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir Metabolite)</title>
        <description>The C0h is the pre-dose plasma concentration.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours post-dose on Weeks 2 and 8</time_frame>
        <population>PK analysis set included all participants who received atleast 1 dose of study drug and had valid pharmacokinetic profile. Here 'n' signifies number of participants analysed for this outcome measure at specific time point.</population>
        <group_list>
          <group group_id="O1">
            <title>SMV 150mg/DCV 60mg/SOF 400mg - Child-Pugh A</title>
            <description>Participants with Child-Pugh score &lt;7 with evidence of portal hypertension (confirmed by presence of esophageal varices or hepatic venous pressure gradient [HVPG] greater than or equal to 10 millimeter of mercury [mm Hg]) received simeprevir (SMV) (150 milligram [mg] capsule), daclatasvir (DCV) (60 mg tablet) and sofosbuvir (SOF) (400 mg tablet) orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>SMV 150mg/DCV 60mg/SOF 400mg - Child-Pugh B</title>
            <description>Participants with Child-Pugh score 7 to 9 (extremes included) received simeprevir (SMV) (150 mg capsule), daclatasvir (DCV) (60 mg tablet) and sofosbuvir (SOF) (400 mg tablet) orally once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-dose (Trough) Concentration (C0h) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir Metabolite)</title>
          <description>The C0h is the pre-dose plasma concentration.</description>
          <population>PK analysis set included all participants who received atleast 1 dose of study drug and had valid pharmacokinetic profile. Here 'n' signifies number of participants analysed for this outcome measure at specific time point.</population>
          <units>nanogram/milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Simeprevir : Week 2 (n = 19, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3577" spread="3685"/>
                    <measurement group_id="O2" value="5218" spread="3461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Simeprevir : Week 8 (n = 16, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3160" spread="3725"/>
                    <measurement group_id="O2" value="8577" spread="7398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daclatasvir : Week 2 (n = 19, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="494" spread="279"/>
                    <measurement group_id="O2" value="646" spread="384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daclatasvir : Week 8 (n = 16, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="492" spread="232"/>
                    <measurement group_id="O2" value="824" spread="476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sofosbuvir : Week 2 (n = 19, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not reported as participants had concentration below the limit of quantification (less than [&lt;]5.00 nanogram/millilter [ng/mL])</measurement>
                    <measurement group_id="O2" value="NA">Data was not reported as participants had concentration below the limit of quantification (less than [&lt;]5.00 nanogram/millilter [ng/mL])</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sofosbuvir : Week 8 (n = 16, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not reported as participants had concentration below the limit of quantification (less than [&lt;]5.00 nanogram/millilter [ng/mL])</measurement>
                    <measurement group_id="O2" value="NA">Data was not reported as participants had concentration below the limit of quantification (less than [&lt;]5.00 nanogram/millilter [ng/mL])</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GS-331007 : Week 2 (n = 19, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="484" spread="236"/>
                    <measurement group_id="O2" value="490" spread="282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GS-331007 : Week 8 (n = 16, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="478" spread="262"/>
                    <measurement group_id="O2" value="572" spread="450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With On-treatment Failure</title>
        <description>On-treatment failure is defined as participants who do not achieve SVR12 and with confirmed detectable HCV RNA at the actual end of study drug treatment.</description>
        <time_frame>Week 12</time_frame>
        <population>The intent-to-treat (ITT) analysis set included all enrolled participants who took at least 1 dose of study drug. Here ‚ÄúN‚Äù (Number of Participants Analyzed) signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>SMV 150mg/DCV 60mg/SOF 400mg - Child-Pugh A</title>
            <description>Participants with Child-Pugh score &lt;7 with evidence of portal hypertension (confirmed by presence of esophageal varices or hepatic venous pressure gradient [HVPG] greater than or equal to 10 millimeter of mercury [mm Hg]) received simeprevir (SMV) (150 milligram [mg] capsule), daclatasvir (DCV) (60 mg tablet) and sofosbuvir (SOF) (400 mg tablet) orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>SMV 150mg/DCV 60mg/SOF 400mg - Child-Pugh B</title>
            <description>Participants with Child-Pugh score 7 to 9 (extremes included) received simeprevir (SMV) (150 mg capsule), daclatasvir (DCV) (60 mg tablet) and sofosbuvir (SOF) (400 mg tablet) orally once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With On-treatment Failure</title>
          <description>On-treatment failure is defined as participants who do not achieve SVR12 and with confirmed detectable HCV RNA at the actual end of study drug treatment.</description>
          <population>The intent-to-treat (ITT) analysis set included all enrolled participants who took at least 1 dose of study drug. Here ‚ÄúN‚Äù (Number of Participants Analyzed) signifies those participants who were evaluable for this outcome measure.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Viral Relapse</title>
        <description>Viral relapse is defined as participants who do not achieve SVR12, with undetectable HCV RNA at the actual end of study drug treatment and confirmed HCV RNA greater than or equal to (&gt;=) LLOQ (15 IU/mL) at Week 16, 24 or 36.</description>
        <time_frame>Week 16, 24 and 36</time_frame>
        <population>The ITT analysis set who failed achieving SVR. Since all participants achieved SVR, the number of participants for this endpoint (viral relapse) analysis was zero.</population>
        <group_list>
          <group group_id="O1">
            <title>SMV 150mg/DCV 60mg/SOF 400mg - Child-Pugh A</title>
            <description>Participants with Child-Pugh score &lt;7 with evidence of portal hypertension (confirmed by presence of esophageal varices or hepatic venous pressure gradient [HVPG] greater than or equal to 10 millimeter of mercury [mm Hg]) received simeprevir (SMV) (150 milligram [mg] capsule), daclatasvir (DCV) (60 mg tablet) and sofosbuvir (SOF) (400 mg tablet) orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>SMV 150mg/DCV 60mg/SOF 400mg - Child-Pugh B</title>
            <description>Participants with Child-Pugh score 7 to 9 (extremes included) received simeprevir (SMV) (150 mg capsule), daclatasvir (DCV) (60 mg tablet) and sofosbuvir (SOF) (400 mg tablet) orally once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Viral Relapse</title>
          <description>Viral relapse is defined as participants who do not achieve SVR12, with undetectable HCV RNA at the actual end of study drug treatment and confirmed HCV RNA greater than or equal to (&gt;=) LLOQ (15 IU/mL) at Week 16, 24 or 36.</description>
          <population>The ITT analysis set who failed achieving SVR. Since all participants achieved SVR, the number of participants for this endpoint (viral relapse) analysis was zero.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With SVR12 Who Maintain to Have HCV RNA &lt;LLOQ Until the End of 5 Years Follow up</title>
        <description>Percentage of participants with SVR12 who continue to have HCV RNA &lt;LLOQ (15 IU/mL) will be reported after the completion of the follow-up phase.</description>
        <time_frame>Week 24 up to Week 276</time_frame>
        <posting_date>01/2021</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>SMV 150mg/DCV 60mg/SOF 400mg - Child-Pugh A</title>
          <description>Participants with Child-Pugh score &lt;7 with evidence of portal hypertension (confirmed by presence of esophageal varices or hepatic venous pressure gradient [HVPG] greater than or equal to 10 millimeter of mercury [mm Hg]) received simeprevir (SMV) (150 milligram [mg] capsule), daclatasvir (DCV) (60 mg tablet) and sofosbuvir (SOF) (400 mg tablet) orally once daily for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>SMV 150mg/DCV 60mg/SOF 400mg - Child-Pugh B</title>
          <description>Participants with Child-Pugh score 7 to 9 (extremes included) received simeprevir (SMV) (150 mg capsule), daclatasvir (DCV) (60 mg tablet) and sofosbuvir (SOF) (400 mg tablet) orally once daily for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 17.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 17.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Skin mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Leader Hepatitis C, GCO ED&amp;CP</name_or_title>
      <organization>Janssen Research &amp; Development, a division of Janssen Pharmaceutica NV</organization>
      <email>ClinicalTrialDisclosure@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

